Abstract
Sphingolipids (SL) are both fundamental structural components of the eukaryotic membranes and signaling molecules that regulate a variety of biological functions. The highly-bioactive lipids, ceramide and sphingosine-1-phosphate, have emerged as important regulators of cardiovascular function in health and disease. In this review we discuss recent insights into the role of SLs, particularly ceramide and sphingosine-1-phosphate, in the pathophysiology of the cardiovascular system. We also highlight advances into the molecular mechanisms regulating serine palmitoyltransferase, the first and rate-limiting enzyme of de novo SL biosynthesis, with an emphasis on the recently discovered inhibitors of serine palmitoyltransferase, ORMDL and NOGO-B proteins. Understanding the molecular mechanisms regulating this biosynthetic pathway may lead to the development of novel therapeutic approaches for the treatment of cardiovascular diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 807-819 |
| Number of pages | 13 |
| Journal | Trends in endocrinology and metabolism: TEM |
| Volume | 27 |
| Issue number | 11 |
| DOIs | |
| State | Published - 1 Nov 2016 |
Keywords
- cardiovascular diseases
- Nogo-B
- sphingolipids
- SPT
Fingerprint
Dive into the research topics of 'Sphingolipid De Novo Biosynthesis: A Rheostat of Cardiovascular Homeostasis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver